# US 11,028,397 B2 · 5′-triphosphate oligoribonucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,397 B2
- Document ID: US11028397B2
- Status: Granted
- Kind: B2
- Application number: 16/217,735
- Filed: 2018-12-12
- Published: 2019-09-26
- Granted: 2021-06-08
- Earliest claimed: 2014-07-18
- Assignees: Oregon Health & Science University
- Applicants: Oregon Health & Science University
- Inventors: John Hiscott
- Web page: https://patentgrep.com/patent/US11028397B2

## CPC

- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/31: Combination therapy
- C12N 2760/16123: Virus like particles [VLP]
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are synthetic oligoribonucleotides that form hairpin loop structures. The oligoribonucleotides can be used in the treatment of viral infection including prophylactic treatments. The oligoribonucleotides can also be used as adjuvants.

## Claims

### Claim 1

A synthetic oligoribonucleotide at least 41 nucleotides in length that can form a hairpin structure comprising at least 17 base pairs, the synthetic oligoribonucleotide comprising a 5′ end triphosphate group, wherein the synthetic oligoribonucleotide comprises SEQ ID NO: 17.

### Claim 2 (depends on 1)

The synthetic oligoribonucleotide of claim 1, incorporated into a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising the synthetic oligoribonucleotide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3 further comprising a viral antigen.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4 formulated as a vaccine.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5 comprising an influenza virus like particle.

### Claim 7 (depends on 3)

A method of treating a viral infection, the method comprising administering an effective amount of the pharmaceutical composition of claim 3 to a subject.

### Claim 8 (depends on 7)

The method of claim 7 wherein the viral infection is caused by dengue virus, chikungunya virus, or influenza virus.

### Claim 9 (depends on 1)

An antiviral composition comprising the synthetic oligoribonucleotide of claim 1.

### Claim 10 (depends on 9)

A method of inducing an antiviral response against a viral infection comprising administering to a subject the antiviral composition of claim 9.

### Claim 11 (depends on 10)

The method of claim 10 wherein viral infection is caused by dengue virus, chikungunya virus, or influenza virus.